Med Page Today

MARCH 21, 2024

(MedPage Today) -- How patients with acute decompensated heart failure (HF) perceived the financial challenges of their healthcare played out in their health outcomes, despite receiving life-prolonging medications, a prospective study from China.

Heart Failure 110

Heart Failure Outcomes 110

Frontiers in Cardiovascular Medicine

MARCH 5, 2025

The association between ACC and clinical outcomes in HF patients was analyzed using Cox proportional hazards regression and restricted cubic spline models.ResultsA total of 4,737 heart failure patients were included. Patients were stratified into three groups based on ACC levels.

Heart Failure 52

Heart Failure Hospital Outcomes Research 52

Cardiology Update

AUGUST 4, 2024

Despite proven benefits in reducing morbidity and mortality, many heart failure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). ESC Heart Failure 2024; 11 : 560–569. The post Digital Consults to Enhance Heart Failure Treatment: The ADMINISTER Trial appeared first on Cardiology Update.

Heart Failure 119

Heart Failure ACE Inhibitor COVID-19 Quality of Life 119

Heart BMJ

JANUARY 29, 2025

Background We evaluated the potential of circulating bone morphogenetic protein 10 (BMP10) as a biomarker for atrial stress and remodelling in patients with heart failure (HF), in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP). We also assessed the predictive value of BMP10 for adverse clinical outcomes.

Heart Failure 52

Heart Failure Circulation Biomarkers Atrial Fibrillation 52

Cardiology Update

JANUARY 22, 2024

The Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT; NCT00251251 ) demonstrated a greater 5-year mortality benefit for patients receiving cardiac-resynchronization therapy (CRT) compared to those receiving implantable cardioverter–defibrillators (ICDs). Secondary outcomes were experienced by 77.7%

Heart Failure 115

Heart Failure Defibrillator Heart Transplant Transplant 115

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Kidney Disease Research 52

Heart BMJ

FEBRUARY 12, 2025

Background Atrial arrhythmias (AA) and heart failure (HF) are major causes of hospitalisation in adult congenital heart disease (ACHD). Dates of first AA and HF presentations were documented, and outcomes of RFA, including acute and long-term success, were assessed.

Congenital Heart Disease 59

Congenital Heart Disease Heart Failure Congenital Arrhythmia 59

Heart BMJ

MARCH 26, 2025

Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 Therefore, early identification of HF in high-risk populations, particularly post-MI, is essential for improving outcomes.

Myocardial Infarction 52

Myocardial Infarction Preserved Ejection Fraction Heart Failure Aortic valve 52

Frontiers in Cardiovascular Medicine

MARCH 5, 2025

IntroductionHeart failure (HF) with improved ejection fraction (HFimpEF) was shown to be related with improved outcome but increase of left ventricular ejection fraction (LVEF) in patients without HF is of less known clinical significance.

Heart Failure 52

Heart Failure Outcomes Academic Research 52

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background The aim of this study was to identify significant factors affecting the effectiveness of exercise training using information of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) study.

Exercise 111

Exercise Heart Failure Outcomes Hospital 111

Frontiers in Cardiovascular Medicine

JANUARY 19, 2025

AimThe association between red cell distribution widthalbumin ratio (RAR) and the risk of all-cause mortality in intensive care unit (ICU) patients with heart failure remains uncertain. database was utilized for the analysis of ICU patients with heart failure.

Heart Failure 52

Heart Failure ICU Physiology Outcomes 52

Cardiology Update

APRIL 25, 2024

RELIEVE-HF investigators evaluated the efficacy and safety of the V-wave interatrial shunt system in patients with heart failure. The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. April 6, 2024.

Heart Failure 98

Heart Failure Heart Transplant Transplant Research 98

DAIC

MAY 2, 2024

(‘Reprieve’), a development stage company focused on pioneering an intelligent approach to acute decompensated heart failure (ADHF) treatment, today highlighted the publication of TREAT-AHF study results in JACC: Heart Failure. Heart failure (HF) is a leading cause of hospitalization in the United States.

Heart Failure 105

Heart Failure Inpatient Hospital Research 105

Frontiers in Cardiovascular Medicine

JANUARY 13, 2025

ObjectiveThis network meta-analysis was to compare the efficacy of different drugs on cardiac function, renal function, and clinical outcomes in patients with acute heart failure (AHF) accompanied by renal dysfunction.MethodsPubMed, EMBASE, Cochrane Library, and Web of Science were searched to screen all clinical trials of AHF between January 1st 2001 (..)

Heart Failure 52

Heart Failure Cardiac Function Outcomes 52

HCPLive

AUGUST 1, 2024

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

Heart Failure 69

Heart Failure Obesity Outcomes 69

DAIC

SEPTEMBER 19, 2024

recently announced that Digitiva, a non-invasive digital health solution for heart failure management, has been listed with the U.S. a smartphone app designed for heart failure patients and built on the Welldoc, Inc. tim.hodson Thu, 09/19/2024 - 09:42 Sept. 18, 2024 – Astellas Pharma Inc.

Heart Failure 105

Heart Failure Technology Biomarkers Innovation 105

Frontiers in Cardiovascular Medicine

JANUARY 22, 2025

IntroductionThe objective of this study was to examine the impact of ventricular assist device support as a bridge to heart transplantation in children with end-stage heart failure. The primary outcome was survival at the follow-up evaluation.

Heart Transplant 52

Heart Transplant Transplant Pediatrics Heart Failure 52

Open Heart

FEBRUARY 27, 2025

Background Iron deficiency (ID) is a highly prevalent comorbidity in patients with chronic and acute heart failure and is associated with worse clinical outcomes. We aimed to evaluate the prevalence and clinical characteristics of ID and its association with in-hospital congestion and postdischarge outcomes.

Heart Failure 52

Heart Failure Hospital Outcomes 52

DAIC

JULY 30, 2024

This study by Fujita Health University researchers revealed that kidney function, considered in terms of estimated glomerular filtration rate (eGFR), can be used as a predictor for SCD in patients with congestive heart failure. During the follow-up period, 198 of these patients suffered from SCD.

Sudden Cardiac Death 111

Sudden Cardiac Death Heart Failure Risk Factors Kidney Disease 111

DAIC

APRIL 3, 2024

healthcare providers can now detect Low EF, a key heart failure indicator, in 15 seconds using an Eko stethoscope during a routine physical examination. As a result, many heart failure cases go undiagnosed until symptoms force a specialist or emergency hospital visit, leading to worse patient outcomes and exacerbated healthcare costs.2

Heart Failure 111

Heart Failure Cardiomyopathy AFIB Hospital 111

JAMA Cardiology

NOVEMBER 16, 2024

This multicenter secondary analysis of the FINEARTS-HF randomized clinical trial examines the treatment effect of finerenone, relative to placebo, on clinical outcomes based on postrandomization potassium levels.

Heart Failure 100

Heart Failure Outcomes 100

DAIC

FEBRUARY 26, 2024

milla1cf Mon, 02/26/2024 - 12:40 February 26, 2024 — More than 6 million Americans live with heart failure , and about half have an enlarged left ventricle, which causes stress on the heart and less blood pumped with each heartbeat. Patients may experience trouble breathing and fatigue, and at times require hospitalization.

Heart Failure 119

Heart Failure Open-Heart Surgery Hospital Outcomes 119

Cardiovascular Diabetology

JULY 22, 2024

Heart failure with preserved ejection fraction (HFpEF) is a mortal clinical syndrome without effective therapies. Empagliflozin (EMPA) improves cardiovascular outcomes in HFpEF patients, but the underlying mec.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Outcomes Research 105

Open Heart

OCTOBER 31, 2024

Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Our findings suggest that monitoring and managing SUA could be crucial in improving patient with HF outcomes. Serum uric acid (SUA), a product of purine metabolism, has been implicated in HF progression.

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Biomarkers 52

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81

DAIC

JULY 31, 2024

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure 111

Heart Failure Preserved Ejection Fraction Research Hospital 111

DAIC

JULY 25, 2024

FDA granted CardiAMP Cell Therapy a Breakthrough Device Designation for the treatment of ischemic heart failure. Leslie Miller, MD , trial investigator at the CHF Heart Function Clinic at BayCare Morton Plant Hospital in Clearwater, Florida and a member of the CardiAMP Heart Failure II Study Executive Steering Committee. “As

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

DAIC

MARCH 7, 2024

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (2.9%

Heart Failure 105

Heart Failure Biomarkers Reimbursement CMS 105

Frontiers in Cardiovascular Medicine

MARCH 7, 2024

Background Belt electrode skeletal muscle electrical stimulation (B-SES) is an emerging therapy anticipated to yield more favorable outcomes than conventional neuromuscular electrical stimulation (NMES), owing to its larger stimulation area. However, information on its efficacy and safety in patients with heart failure remains limited.

Heart Failure 124

Heart Failure Obesity Heart Transplant Transplant 124

HeartRhythm

MARCH 28, 2025

Data supporting the role of primary prevention ICDs in patients with heart failure were generated by rigorous randomized controlled trials (RCTs).1 1 During this time period, numerous advances in ICD technology, care, and follow-up have resulted in unequivocal improvement in the outcomes of patients with an ICD.

Defibrillator 40

Defibrillator Heart Failure Sudden Cardiac Death Technology 40

European Journal of Heart Failure

FEBRUARY 16, 2025

Baseline characteristics for the vericiguat global study in participants with chronic heart failure (VICTOR) trial. of participants had no prior hospitalization for heart failure. Conclusion The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. beta-blockers, 94.3%

Heart Failure 40

Heart Failure Defibrillator Hospital Outcomes 40

DAIC

FEBRUARY 6, 2024

Matthew Segar co-authored a study in JACC Heart Failure led by his research and residency mentor, University of Texas Southwestern Medical Center's Dr. Ambarish Pandey , that utilized a machine learning-based-approach to identify, understand, and predict diuretic responsiveness in patients with acute decompensated heart failure (ADHF).

Heart Failure 111

Heart Failure Research Hospital Cardiovascular Disease 111

HCPLive

MARCH 30, 2025

Dapagliflozin lowered the incidence of all-cause death or worsening of heart failure versus standard care in the DapaTAVI trial at ACC.25.

Heart Failure 64

Heart Failure Outcomes 64

Open Heart

JANUARY 19, 2025

Introduction Data on the characteristics and outcomes of pregnancy and among patients with Fontan physiology are limited. We aimed to evaluate the immediate and long-term outcomes among these patients who were followed at our centre. We examined maternal and obstetric outcomes.

Congenital Heart Disease 52

Congenital Heart Disease Outcomes Physiology Arrhythmia 52

DAIC

MARCH 13, 2024

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

MARCH 1, 2024

In a new study published in JACC: Heart Failure , maternal loss of a partner or child shortly before or during pregnancy was found to be associated with increased risk of heart failure up to middle-age in the child. According to the World Heart Federation, more than 64 million people worldwide have heart failure.

Heart Failure 105

Heart Failure Public Health Cardiovascular Disease Research 105

Circulation: Heart Failure

MARCH 14, 2025

Circulation: Heart Failure, Ahead of Print. The genotype-phenotype interdependence causes unpredictable phenotypic penetrance that results in a variety of signs and symptoms and patient outcomes. About 3% to 4% of patients with African ancestry carry this genetic predisposition to develop signs and symptoms of hATTR-CA.

Genetic predisposition 71

Genetic predisposition Heart Failure Biomarkers Circulation 71